why choose us

First received: July 4, 2022

Clinical Trial: Neoadjuvant Anti-PD1 in HCC

Study Status: Completed

Recruit Status: Completed

Condition: Hepatocellular Carcinoma
HCC
Liver Cancer

Study Type: Interventional


Official Title: Neoadjuvant Immunotherapy With Anti-PD1 in Borderline Resectable Hepatocellular Carcinoma

Brief Summary: This is a phase 2, single-arm trial designed to assess the clinical benefit of treatment with nivolumab administered in patients with untreated, borderline resectable HCC.

Read more